arrow
M

Matthew A. Powell

Duke University
H指数:50
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol

前瞻性评估恶性腹水细胞学在子宫内膜癌中预后意义:一项NRG Oncology/妇科肿瘤学组关于GOG-210方案的研究

2025-09-030
PRE
Time Course Of Adverse Events In Primary Advanced Or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy In The ENGOT-EN-6-NSGO/GOG-3031/RUBY Trial

ENGOT-EN-6-NSGO/GOG-3031/RUBY试验中,接受多塔利单抗联合化疗治疗的原发性晚期或复发性子宫内膜癌患者不良事件的时间进程

2025-02-010
PRE
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258

子宫内膜癌(EC)的分子分类及其与无复发生存期(RFS)和总生存期(OS)结局的关联:GOG-0258研究的附加分析

2025-02-011
PRE
A Plain Language Summary of Dostarlimab for primary advanced or recurrent endometrial cancer
2024-07-010
PRE
Stromal cell DDR2 promotes ovarian cancer metastasis
2024-03-040
PRE
A combined RAD51 and phosphorylated replication protein assay predict response to platinum chemotherapy in high-grade serous ovarian cancer
2024-03-040
PRE
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer

在1b期研究中,结合PARP和MEK抑制,有或没有anti-PD-L1,对BRCA野生型,铂敏感,复发性卵巢癌患者的主要结果和特征

CANCER
IF5.1
2024-01-301
OAAI
Stromal DDR2 Promotes Ovarian Cancer Metastasis through Regulation of Metabolism and Secretion of Extracellular Matrix Proteins
2023-08-017
PRE
Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival
2023-07-0315
OAAI
Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer
2023-07-011
PRE
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
2023-06-08294
OA
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
2023-06-08246
OA